SPRY

ARS Pharmaceuticals, Inc. (SPRY) SWOT Analysis Analysis (2026)

Invetso Score: 3.9/10 — Weak · Last Updated: 2026-08-01

Strengths

Gross margin remains strong at 77.1%, indicating solid product economics.

Current ratio of 4.94 and quick ratio of 4.77 show a very strong liquidity position.

Cash per share of 2.02 exceeds revenue per share of 1.00, supporting near-term flexibility.

Weaknesses

TTM profitability remains deeply negative, with net profit margin at -200.0% and operating margin at -204.5%.

Return on equity is -153.6% and return on invested capital is -85.0%, reflecting poor capital efficiency.

Operating cash flow and free cash flow are both negative, with free cash flow per share at -1.77.

Opportunities

A high gross margin base leaves room for operating leverage if spending discipline improves.

Strong liquidity gives the company flexibility to fund development and commercialization without immediate financing pressure.

Low price-to-sales of 6.05 and negative earnings can support upside if revenue growth accelerates and losses narrow.

Threats

Interest coverage is deeply negative at -82.9, underscoring ongoing operating losses and financing risk.

Cash conversion remains weak with a cash conversion cycle of 174.9 days and operating cash flow ratio of -3.53.

High leverage metrics, including debt-to-equity of 1.57 and financial leverage of 4.69, increase downside risk if losses persist.

Overall Score

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on ARS Pharmaceuticals, Inc.. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →